viewTissue Regenix Group PLC

Tissue Regenix Group - DermaPure Product Line Extension Launched

RNS Number : 5699O
Tissue Regenix Group PLC
03 October 2019

Tissue Regenix Group plc

Tissue Regenix launches DermaPure® product line extension specifically for surgical and trauma markets

Leeds, 3 October 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group"), the regenerative medical devices company, announces the launch of a product line extension, 'DermaPure Non- Oriented', specifically tailored for the surgical and trauma markets, which further expands the reach of its flagship dCELL® Technology product, DermaPure.

DermaPure Non-Oriented, processed utilizing the Company's patented dCELL® Technology, has two identical sides, meaning the orientation of the graft is not a factor during application or implantation. This will enhance ease of application, whilst also maintaining the acellular scaffold and thereby promoting tissue regeneration.

The primary indication for this product line will be uro-gynecological procedures, where the Group already has a strong working relationship with partner and specialist distributor, ARMS Medical.  Last week, the product was unveiled at the American Urogynecologic Society annual meeting in Nashville, TN, and is now available for distribution, initially sized 7x10cm.  

Gareth Jones, interim CEO, Tissue Regenix Group commented: "Our commercial success is predicated on our ability to identify new clinical applications and rapidly develop product lines to meet this demand. Working closely with our strategic partner, ARMS Medical, we are confident that DermaPure Non-Oriented will offer our clinicians the clinical outcomes and health economic benefits they require. We continue to see the growing demand for DermaPure, as demonstrated in our recent interim results, and expect that DermaPure Non-Oriented will augment this product portfolio, driving adoption by physicians in the future."

For more Information:


Tissue Regenix Group plc

Caitlin Pearson                                 Head of Communications  

Tel: 0330 430 3073 / 07920272 441



Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Jonathan Senior / Alex Price / Ben Maddison

Tel:  0207 710 7600




FTI Consulting 

Brett Pollard / Victoria Foster Mitchell / Mary Whittow

Tel: 0203 727 1000



About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.





This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Tissue Regenix Group PLC

Price: 0.35

Market: AIM
Market Cap: £24.62 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016